Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | MDM4 | O15151 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20825490 | 1.00 | MDM2 (0.42) | MDM2MDM4TP53NFKB1NFKB2 | |
| SCHEMBL20825773 | 0.93 | MDM2 (0.48) | MDM2MDM4TP53CASP3TNF | |
| SCHEMBL29635950 | 0.89 | MDM2 (0.41) | MDM2MDM4TP53NFKB1NFKB2 | |
| SCHEMBL24633710 | 0.89 | MDM4 (0.47) | MDM4TP53CASP3TNFTLR2 | |
| SCHEMBL25260682 | 0.89 | MDM4 (0.47) | MDM4TP53CASP3TNFTLR2 | |
| SCHEMBL25260680 | 0.89 | MDM4 (0.47) | MDM4TP53CASP3TNFTLR2 | |
| SCHEMBL25657544 | 0.85 | MDM4 (0.46) | MDM4TP53CASP3TNFTLR2 | |
| SCHEMBL22579992 | 0.85 | MDM2 (0.48) | MDM2MDM4TP53CASP3TNF | |
| SCHEMBL22433327 | 0.85 | MDM2 (0.48) | MDM2MDM4TP53CASP3TNF | |
| SCHEMBL22552766 | 0.85 | MDM2 (0.48) | MDM2MDM4TP53CASP3TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279735-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| WO-2019052545-A1 | CYCLIC PEPTIDE ANTIBIOTICS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | NPPA, LNPEP, CLPP | MDM2 2362/4885MDM4 3536/4885TP53 2216/4885 |
| US-11279735-B2 | Cyclic peptide antibiotics | NPPA, LNPEP, CLPP | MDM2 2362/4885MDM4 3536/4885TP53 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.